Results 81 to 90 of about 5,762,549 (184)

Therapeutic Antibodies Targeting CSF1 Impede Macrophage Recruitment in a Xenograft Model of Tenosynovial Giant Cell Tumor [PDF]

, 2010
Tenosynovial giant cell tumor is a neoplastic disease of joints that can cause severe morbidity. Recurrences are common following local therapy, and no effective medical therapy currently exists.
Gao, Doris, Yuzhuo Wang, Wang, Y.Z., West, Robert, Paul W. Clarkson, Clarkson, Paul, Torsten O. Nielsen, Cheng, Hongwei, Hongwei Cheng, Dongxia Gao, Abraham, Judith, Marina Pacheco, Nielsen, Torsten   +12 more
core   +2 more sources

Arthroscopic resection of localized tenosynovial giant cell tumor in the deep infrapatellar bursa: a case report

, 2023
Tenosynovial giant cell tumor (TGCT) is a rare disease characterized by the proliferation of the synovial membrane of a joint, tendon sheath, or bursa. TGCTs in joints are subdivided into the diffuse or localized type.
Dimnjaković, Damjan, Damjan Dimnjaković, Ivan Bojanić, Bojanić, Ivan   +3 more
core   +1 more source

Achilles and flexor hallucis longus tendonitis or giant cell tumor?: A case study

Foot & Ankle Surgery: Techniques, Reports & Cases
Tenosynovial giant cell tumors (TGCT), are benign proliferative lesions arising from the tendon sheaths, synovium, or bursae. They commonly occur in the extremities and may present as localized or diffuse forms.
Julie Lin, DPM, Sophia Bacarella, DPM, Jonathan Edelstien, DPM, Rick Delmonte, DPM, Jeffrey Lucido, DPM   +4 more
doaj   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2024: A year in review

British Journal of Pharmacology, Volume 182, Issue 7, Page 1416-1445, April 2025.
Abstract In the past year, the European Medicines Agency (EMA), the Food and Drug Administration (FDA) and the Medicines and Healthcare Products Regulatory Agency (MHRA) authorised 53 novel drugs. While the 2024 harvest is not as rich as in 2023, when 70 new chemical entities were approved, the number of ‘orphan’ drug authorisations in 2024 (21) is ...
Stavros Topouzis, Andreas Papapetropoulos, Steve P. H. Alexander, Miriam Cortese‐Krott, Dave A. Kendall, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Mauro M. Teixeira, Nathalie Vergnolle, Xin Wang, Péter Ferdinandy   +16 more
wiley   +1 more source

Racial Distribution of Tenosynovial Giant Cell Tumor

Objectives: Tenosynovial giant cell tumor (TGCT) is a rare mesenchymal tumor driven by overexpression of colony-stimulating factor 1 (CSF1) in a few neoplastic synovial cells.
Malena Jhonson, Ankit Mangla, Felicia Tejawinata, Pingfu Fu   +3 more
core   +1 more source

Randomized placebo-controlled double-blind phase II study of zaltoprofen for patients with diffuse-type and unresectable localized tenosynovial giant cell tumors: a study protocol

BMC Musculoskeletal Disorders, 2019
Background A tenosynovial giant cell tumor (TGCT) is a locally aggressive benign neoplasm arising from intra- or extra-articular tissue. Diffuse TGCT (D-TGCT) most commonly develops in the knee, followed by the hip, ankle, elbow, and shoulder.
Akihiko Takeuchi, Akihiro Nomura, Norio Yamamoto, Katsuhiro Hayashi, Kentaro Igarashi, Susumu Tandai, Akira Kawai, Akihiko Matsumine, Shinji Miwa, Yoshihiro Nishida, Tomoki Nakamura, Ryu Terauchi, Manabu Hoshi, Toshiyuki Kunisada, Makoto Endo, Kenichi Yoshimura, Toshinori Murayama, Hiroyuki Tsuchiya   +17 more
doaj   +1 more source

Vimseltinib: A novel colony stimulating factor 1 receptor (CSF1R) inhibitor approved for treatment of tenosynovial giant cell tumors (TGCTs)

Intractable & Rare Diseases Research
A tenosynovial giant cell tumor (TGCT) is a rare benign neoplasm arising from the tendon sheaths, bursae, or synovial lining of joints and is characterized by locally aggressive growth and the potential for recurrent disease. Surgery is still the main form of treatment for a TGCT, but these neoplasms, and most notably the diffuse type, exhibit a high ...
Dou, Fangzhou, Lu, Daoran, Gao, Jianjun
openaire   +2 more sources

DataSheet_1_Expanding the molecular spectrum of tenosynovial giant cell tumors.docx

, 2022
BackgroundWhile great advances in clinical and pathological description of tenosynovial giant cell tumors (TGCT) have been made, TGCT molecular heterogeneity represents an ongoing challenge.
Marie Karanian (8871731), Armelle Dufresne (3451430), Amine Bouhamama (8871737), Alexandra Meurgey (8871734), Daniel Pissaloux (155403), Thibault Gauduchon (14097066), Philippe Cassier (3451427), Helene Vanacker (14097069), Isabelle Ray-Coquard (346757), Jean-Yves Blay (72864), Franck Tirode (148508), Mehdi Brahmi (804467), François Gouin (58702)   +12 more
core   +1 more source

Treatment of Tenosynovial Giant Cell Tumor of the Cervical Spine with Postoperative Anti-RANKL Antibody (Denosumab) Administration [PDF]

Tenosynovial giant cell tumor (TGCT) is a fibrous histiocytic tumor originating in the synovial membrane. While cervical TGCT may not be considered a common diagnosis preoperatively because it is relatively rare, it has a high recurrence rate and should ...
Nagase, Takayuki, Sugahara, Chiaki, Oda, Yoshinao, Miyake, Hayato, Yamamoto, Hidetaka, Yasuhara, Takao, Hirata, Yuichi, Ayada, Yoshiyuki, Sasada, Susumu, Tanaka, Shota   +9 more
core   +1 more source

Tenosynovial giant cell tumor in an unusual localization

, 2013
Tenosynovial giant cell tumors are benign tumors that are often localized on the palmar sites of the hand. The involvement of large joints such as the knee and ankle are rare. We present an 18-year-old male patient referred to the orthopedics clinic with
ÖZGÜR, TÜMAY, TUNA, EMİNE BURÇİN, Atik, Esin, KALACI, AYDINER, Tuna, Burcin   +4 more
core   +1 more source